Human CD55/DAF Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG
Catalog Number: BAF2009

DESCRIPTION

Species Reactivity	Human
Specificity	Detects CD55/DAF in Western blots.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived rhCD55 Asp35-Ser353 Accession # P08174
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

APPLICATIONS

Please Note: *Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.*

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human CD55/DAF (Catalog # 2009-CD)
Immunocytochemistry	5-15 µg/mL	See Below
Immunohistochemistry	5-15 µg/mL	Immersion fixed paraffin-embedded sections of human pancreatic cancer tissue

DATA

Immunocytochemistry



CD55/DAF in Human PBMCs. CD55/DAF was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human CD55/DAF Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF2009) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Streptavidin (yellow; Catalog # NL999) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 **Europe | Middle East | Africa** TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956

Human CD55/DAF Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG
Catalog Number: BAF2009

BACKGROUND

CD55, also known as DAF or decay-accelerating factor, is a 70-75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C' activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1-4). A hallmark of RCA proteins is the presence of four to 30 SCRs (short consensus repeats; also called CCPs for C' control protein modules) in their plasma-exposed regions. SCRs are characterized by a 60-65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a β-barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature CD55 is 53% and 84% aa identical to mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated "decay", or dissociation of active C3 convertases, thus blocking the development of C' attack complexes on nonforeign cells (1, 2). Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection (4).

References:

1. Herbert, A. *et al.* (2002) Biochem. Soc. Trans. **30**:990.
2. Miwa, T. and W-C. Song (2001) Int. Immunopharmacol. **1**:445.
3. Hourcade, D. *et al.* (2000) Immunopharmacology **49**:103.
4. Lea, S. (2002) Biochem. Soc. Trans. **30**:1014.
5. Medof, M.E. *et al.* (1987) Proc. Natl. Acad. Sci. USA **84**:2007.
6. Caras, I.W. *et* al. (1987) Nature **325**:545.
7. Lukacik, P. *et al.* (2004) Proc. Natl. Acad. Sci. USA **101**:1279.
8. Moran, P. *et al.* (1991) J. Biol. Chem. **266**:1250.
9. Lublin, D.M. *et al.* (1994) Blood **84**:1276.
10. Williams, P. *et al.* (2003) J. Biol. Chem. **278**:10691.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 **Europe | Middle East | Africa** TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956